AP2014007532A0 - Fibroblast growth factor 21 variants - Google Patents

Fibroblast growth factor 21 variants

Info

Publication number
AP2014007532A0
AP2014007532A0 AP2014007532A AP2014007532A AP2014007532A0 AP 2014007532 A0 AP2014007532 A0 AP 2014007532A0 AP 2014007532 A AP2014007532 A AP 2014007532A AP 2014007532 A AP2014007532 A AP 2014007532A AP 2014007532 A0 AP2014007532 A0 AP 2014007532A0
Authority
AP
ARIPO
Prior art keywords
variants
growth factor
fibroblast growth
fibroblast
factor
Prior art date
Application number
AP2014007532A
Other languages
English (en)
Inventor
Ryan James Darling
Radmila Micanovic
Craig Duane Dickinson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46964112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014007532(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AP2014007532A0 publication Critical patent/AP2014007532A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AP2014007532A 2011-10-04 2012-09-25 Fibroblast growth factor 21 variants AP2014007532A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542906P 2011-10-04 2011-10-04
PCT/US2012/057053 WO2013052311A1 (en) 2011-10-04 2012-09-25 Fibroblast growth factor 21 variants

Publications (1)

Publication Number Publication Date
AP2014007532A0 true AP2014007532A0 (en) 2014-03-31

Family

ID=46964112

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007532A AP2014007532A0 (en) 2011-10-04 2012-09-25 Fibroblast growth factor 21 variants

Country Status (28)

Country Link
US (2) US8541369B2 (es)
EP (1) EP2763689B1 (es)
JP (1) JP6060167B2 (es)
KR (1) KR20140059271A (es)
CN (1) CN103906530B (es)
AP (1) AP2014007532A0 (es)
AR (1) AR087973A1 (es)
AU (1) AU2012318956A1 (es)
BR (1) BR112014007532A2 (es)
CA (1) CA2843520A1 (es)
CL (1) CL2014000801A1 (es)
CO (1) CO6910165A2 (es)
CR (1) CR20140142A (es)
DO (1) DOP2014000050A (es)
EA (1) EA201490521A1 (es)
EC (1) ECSP14013285A (es)
ES (1) ES2548214T3 (es)
IL (1) IL230754A0 (es)
IN (1) IN2014CN00782A (es)
MA (1) MA35458B1 (es)
MX (1) MX2014004159A (es)
PE (1) PE20142044A1 (es)
PH (1) PH12014500740A1 (es)
SG (1) SG11201401792UA (es)
TN (1) TN2014000096A1 (es)
TW (1) TWI461435B (es)
WO (1) WO2013052311A1 (es)
ZA (1) ZA201400882B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120522T1 (hr) 2007-03-30 2012-08-31 Ambrx Modificirani fgf-21 polipeptidi i njihova uporaba
UA118744C2 (uk) 2011-07-01 2019-03-11 ЕнДжиЕм БАЙОФАРМАСЬЮТІКАЛЗ, ІНК. Химерний пептид, композиція, що його містить, його застосування і способи лікування порушень і захворювань обміну речовин
EA201491856A1 (ru) * 2012-05-15 2015-03-31 Эли Лилли Энд Компани Терапевтическое применение белков фактора роста фибробластов 21
KR20150006059A (ko) * 2012-06-11 2015-01-15 일라이 릴리 앤드 캄파니 섬유모세포 성장 인자 21 변이체
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
NZ630469A (en) 2012-12-27 2017-02-24 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
HUE050279T2 (hu) 2014-01-24 2020-11-30 Ngm Biopharmaceuticals Inc Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
JP6712230B2 (ja) * 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
KR102569907B1 (ko) 2014-10-23 2023-08-24 엔지엠 바이오파마슈티컬스, 아이엔씨. 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
WO2017220706A1 (en) * 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN106397607A (zh) * 2016-09-13 2017-02-15 河南师范大学 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用
CN106220724B (zh) * 2016-09-13 2019-10-11 河南师范大学 人成纤维细胞生长因子21重组蛋白及其制备方法和应用
CN106432509B (zh) * 2016-09-13 2019-05-21 河南师范大学 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用
EP4470551A3 (en) 2017-03-14 2025-02-26 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
KR20200051706A (ko) 2017-09-08 2020-05-13 브리스톨-마이어스 스큅 컴퍼니 비알콜성 지방간염 (nash)을 치료하는 방법에 사용하기 위한 변형된 섬유모세포 성장 인자 21 (fgf-21)
SI3727423T1 (sl) 2017-12-22 2024-08-30 Novartis Ag Zdravljenje metaboličnih motenj z različicami fgf21
US11679143B2 (en) 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
MX2021000016A (es) 2018-07-03 2021-03-09 Bristol Myers Squibb Co Formulaciones de factor de crecimiento de fibroblastos (fgf-21).
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
IL294534A (en) 2020-01-08 2022-09-01 Bristol Myers Squibb Co Fgf-21 conjugate formulations
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases
EP4288461A4 (en) 2021-07-14 2025-07-02 Beijing Ql Biopharmaceutical Co Ltd FUSION POLYPEPTIDES FOR METABOLIC DISORDERS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
KR20060135648A (ko) * 2003-12-10 2006-12-29 일라이 릴리 앤드 캄파니 섬유모세포 성장인자 21의 뮤테인
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP2161281A1 (en) * 2004-09-02 2010-03-10 Eli Lilly & Company Muteins of fibroblast growth factor 21
HRP20120522T1 (hr) 2007-03-30 2012-08-31 Ambrx Modificirani fgf-21 polipeptidi i njihova uporaba
NZ590050A (en) * 2008-06-04 2012-08-31 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
JO3469B1 (ar) 2009-05-05 2020-07-05 Amgen Inc طافرات fgf21 واستخداماتها
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof

Also Published As

Publication number Publication date
WO2013052311A1 (en) 2013-04-11
CO6910165A2 (es) 2014-03-31
US8883726B2 (en) 2014-11-11
EP2763689A1 (en) 2014-08-13
JP2014530220A (ja) 2014-11-17
US8541369B2 (en) 2013-09-24
TW201326198A (zh) 2013-07-01
IN2014CN00782A (es) 2015-04-03
IL230754A0 (en) 2014-03-31
ZA201400882B (en) 2016-02-24
AR087973A1 (es) 2014-04-30
CL2014000801A1 (es) 2014-09-12
PH12014500740A1 (en) 2020-10-19
EP2763689B1 (en) 2015-08-12
TWI461435B (zh) 2014-11-21
PE20142044A1 (es) 2014-12-06
MX2014004159A (es) 2015-02-12
KR20140059271A (ko) 2014-05-15
CA2843520A1 (en) 2013-04-11
US20130085098A1 (en) 2013-04-04
DOP2014000050A (es) 2014-04-15
ES2548214T3 (es) 2015-10-14
EA201490521A1 (ru) 2014-07-30
CR20140142A (es) 2014-05-02
CN103906530B (zh) 2016-01-20
JP6060167B2 (ja) 2017-01-11
SG11201401792UA (en) 2014-08-28
US20130324460A1 (en) 2013-12-05
MA35458B1 (fr) 2014-09-01
AU2012318956A1 (en) 2014-02-06
BR112014007532A2 (pt) 2017-04-04
ECSP14013285A (es) 2014-05-31
CN103906530A (zh) 2014-07-02
TN2014000096A1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
ZA201400882B (en) Fibroblast growth factor 21 variants
ZA201407938B (en) Fibroblast growth factor 21 variants
IL235832A0 (en) Fibroblastic growth factor 21 proteins
PL119929U1 (pl) Konewka
HK1196294A (en) Fibroblast growth factor 21 variants
GB201322227D0 (en) Watering can
PL119928U1 (pl) Konewka
PL119924U1 (pl) Konewka
PL119927U1 (pl) Konewka
PL119925U1 (pl) Konewka
PL119926U1 (pl) Konewka
GB201114530D0 (en) Concept 35
GB201114545D0 (en) Concept 21
GB201114487D0 (en) Concept 16
GB201114486D0 (en) Concept 6
GB201114472D0 (en) Concept 14
GB201103885D0 (en) Concept 58
GB201100366D0 (en) Concept 12 12
GB201114519D0 (en) Concept 31
GB201114523D0 (en) Concept 33
GB201114534D0 (en) Concept 37
GB201114517D0 (en) Concept 15
GB201114535D0 (en) Concept 38
GB201114536D0 (en) Concept 39
GB201114489D0 (en) Concept 12 12